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Available online 17 December 2015AbstractNumerous Chlamydia trachomatis proteins have been identified as potential subunit vaccines, of which the major outer-membrane protein
(MOMP) has, so far, proven the most efficacious. Recently, subunit A of the V-type ATP synthase (ATPase; TC0582) complex was shown to
elicit partial protection against infection. Computational modeling of a neighboring gene revealed a novel subunit of the V-type ATPase
(TC0583). To determine if this newly identified subunit could induce protection and/or enhance the partial protection provided by subunit A
alone, challenge studies were performed using a combination of these recombinant proteins. The TC0583 subunit alone and concurrently with
TC0582, was used to vaccinate BALB/c mice utilizing CpG-1826 and Montanide ISA 720 VG as adjuvants. Vaccinated animals were challenged
intranasally with Chlamydia muridarum and the course of the infection was followed. Mice immunized with individual antigens showed minimal
alleviation of body weight reduction; however, mice immunized with TC0583 and TC0582 in combination, displayed weight loss levels close to
those observed with MOMP. Importantly, immunization with a combination of recombinant subunit proteins reduced chlamydial inclusion
forming units by approximately a log-fold. These protection levels support that, these highly conserved Chlamydia proteins, in combination with
other antigens, may serve as potential vaccine candidates.
© 2015 Published by Elsevier Masson SAS on behalf of Institut Pasteur.
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Chlamydia trachomatis is the most common sexually
transmitted bacterial pathogen and the etiological agent of
trachoma, the most common cause of preventable blindness in
regions of the developing world [1e3]. In addition, this
pathogen causes respiratory and gastrointestinal infections
[2,4]. Attempts to control these organisms using screening
programs and antibiotic treatment have so far failed. In regions
that have implemented these programs, an increase in the
number of C. trachomatis genital infections cases has been* Corresponding author. Tel.: þ1 949 824 7450; fax: þ1 949 824 2160.
E-mail address: Imdelama@uci.edu (L.M. de la Maza).
http://dx.doi.org/10.1016/j.micinf.2015.12.002
1286-4579/© 2015 Published by Elsevier Masson SAS on behalf of Institut Pasteureported [5,6]. Therefore, to control Chlamydia, a vaccine is
likely the most efficacious approach. Decades ago, whole or-
ganism vaccines, tested to protect against trachoma, were
accompanied by a hypersensitivity reaction in some immu-
nized individuals upon re-exposure to this pathogen [2,7,8].
Although the cause of this hypersensitivity reaction is still
under investigation, the possibility that an antigenic compo-
nent of Chlamydia mediated this adverse outcome stimulated
the search for a subunit vaccine [9e13].
Analysis of the humoral immune response in mice infected
with Chlamydia muridarum (previously called C. trachomatis
mouse pneumonitis) showed that protein TC0582 was an
immunodominant antigen [14]. Furthermore, mice vaccinated
with TC0582 were significantly protected against an intranasalr.
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subunit A (AtpA) of a putative V-type ATP synthase encoded
by Chlamydia and shares greater than 50% sequence identity
with its closest homologs (e.g. the bacterial spirochetes Bor-
relia and Treponema). V-type ATP synthase (ATPase) is an
inner membrane associated macromolecular assembly that
couples the transfer of protons, or sodium cations, across
membranes with the synthesis, or hydrolysis, of ATP [16].
Chlamydia encode several proteins with a high degree of
sequence similarity to various subunits of the bacterial V-type
ATPase complex [17]. Analysis of the C. muridarum genome
organization [18] and transcriptional landscape of C. tracho-
matis indicated that six of these subunits (A, B, D, E, K and I)
were transcribed within a single operon [19]. Intriguingly, this
operon also includes a protein of unknown function (TC0583).
BLAST analysis with either ortholog failed to identify any
statistically significant hit outside of Chlamydia. However,
protein structure homology modeling suggests that TC0583
shares a great deal of structural similarity with V-type ATPase
subunit C (AtpC). Subunit C is critical for the function of the
ATPase and is localized within the bacterial cytoplasm. As
part of an ongoing protein structure and function analysis of
TC0583, it was hypothesized that TC0583 could be effective
as a vaccine antigen and furthermore may enhance the
immunoprotective capabilities of TC0582. To test these pre-
mises, mice were vaccinated with TC0582, TC0583, or a
combination of both proteins and challenged with C.
muridarum.
2. Materials and methods2.1. Growth of C. muridarum stocksThe C. muridarum (MoPn; strain Nigg II; ATCC VR 123)
was purchased from the American Type Culture Collection
(Manassas, VA, USA). Stocks of Chlamydia elementary
bodies (EB) were prepared as previously described [20].2.2. Cloning, expression and purification of recombinant
C. muridarum TC0583, TC0582 and MOMPThe entire open reading frame of TC0583 (residues
1e266), from C. muridarum genomic DNA, was amplified via
PCR and subcloned into SspI-digested pTBMalE through
ligation independent cloning [21] using the following primers:
F: 50- CTGTACTTCCAATCCAATATTATGAATCAA-
TATTATTTT-30 and R: 50- CCGTTATCCACTTCCAA-
TATTCTACCATTTGATTCCTTTCTC-3’. The pTBMalE
vector encodes both N-terminal His6 and maltose binding
protein (MBP) tags. After DNA sequence verification, the
vector was transformed into competent Escherichia coli
(Rosetta 2(DE3) pLysS). Cells were grown to an OD600 of
~1.5 at 37 C within Terrific Broth supplemented with ampi-
cillin (100 mg ml1) and chloramphenicol (30 mg ml1).
Turbid cultures were rapidly cooled in an ice bath for 5 min
and protein expression was induced overnight at 16 C by the
addition of isopropyl 1-thio-b-D-galactopyranoside (IPTG) toa 1 mM final concentration. Centrifugation was used to harvest
bacterial cells, followed by sonication in lysis buffer [20 mM
TriseHCl (pH 8.0), 500 mM NaCl, and 10 mM imidazole].
The cell homogenate was clarified by centrifugation and the
soluble His6/MBP-tagged protein was collected in the super-
natant. Sequential purification of the target protein was per-
formed on Ni2þ-NTA-Sepharose and MBPTrap HP (GE
Lifesciences) columns, respectively. The purified protein was
concentrated to 6 mg ml1 in 20 mM TriseHCl (pH 8.0),
500 mM NaCl, 20 mM maltose and stored at 4 C.
The TC0582 gene was amplified with Pfu Turbo DNA
Polymerase (Stratagene, La Jolla, CA) using the following
primers: F: 50-C ATGCCATGGTAGCAACTTCAAAAGA-30
and R: 50-ATAGTTTAGCGGCCGCCGTCTGCAC-
CATTTTGC-30 and the DNA was cloned into the pET-45b
vector (Novagen, Gibbstown, NJ) as previously described
[15] The TC0582 His-tagged protein was extracted and puri-
fied from E. coli inclusion bodies using the Invitrogen Pro-
Bond™ (Carlsbad, CA). The MOMP gene, without the signal
sequence, was amplified, expressed and MOMP purified as
previously described [22]. Before immunization TC0582 and
MOMP were dialyzed against PBS (pH 7.4) with 0.05% Z3-14
and stored at 80 C [23,15]. Using the limulus amoebocyte
assay (BioWhittaker, Inc., Walkersville, MD), the recombinant
antigens were found to have less than 0.05 EU of LPS/mg of
protein.2.3. Computational modeling of TC0583, multiple
sequence alignment and figure modelingThe entire amino acid sequence (residues 1e266) of C.
muridarum TC0583 was submitted to the protein structure
prediction platform I-TASSER [24e26] for computational
modeling. The Local-Global Alignment method [27] was used
to superimpose three-dimensional structures and all repre-
sentative images were generated using PyMol [28]. ClustalW
[29] was utilized for multiple sequence alignments, which
were then aligned with secondary structure elements using
ESPRIPT [30].2.4. Vaccination protocolsThree-weeks-old female BALB/c (H-2d) mice (Charles
River Laboratories; Wilmington, MA) were housed at the
University of California, Irvine, Vivarium. The University of
California, IACUC approved all animal protocols.
The adjuvants CpG-1826 (TriLink, San Diego, CA; 10 mg/
mouse/immunization) and Montanide ISA 720 VG (SEPPIC
inc., Fairfield, NJ; 70% of total vaccine volume) were directly
mixed with antigens (TC0582, TC0583 or MOMP: 10 mg of
each antigen/mouse/immunization) or antigen combinations
(TC0582 þ TC0583: 10 mg of each antigen/mouse/immuni-
zation) [31,32]. Montanide ISA 720 VG was administered
only by systemic routes. The quantification of TC0583 was
done subtracting the amount corresponding to the MBP tag.
Mice were immunized twice intranasally (i.n.), followed
twice by the intramuscular plus subcutaneous (i.m./s.c.)
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immunized with CpG-1826 and Montanide ISA 720 VG in
PBS (PBS-C/M). A negative control group was inoculated
once i.n. with 20 ml of minimal essential medium (MEM). As
positive vaccine controls, mice were immunized i.n. once with
104 inclusion forming units (IFU) of C. muridarum. As a
positive recombinant antigen control mice were vaccinated
with rMOMP and the two adjuvants [33,31]. All mice were
challenged i.n. with 104 IFU of C. muridarum four weeks after
the last immunization.2.5. Characterization of the humoral and cell mediated
immune responses following vaccinationTo measure C. muridarum-specific antibodies, following
vaccination, blood was collected from each mouse the day
before the challenge. ELISAs were performed as previously
describedwith EB, or recombinant proteins, as antigens [32,22].
To assess the T-cell memory response a lymphoproliferative
assay was performed before the i.n. challenge as described
[34,33]. Briefly, spleens were harvested and disrupted. T cell-
enriched lymphocytes were isolated through a nylon wool col-
umn and were cultured with accessory cells for antigen pre-
sentation (prepared by irradiating (3000 rad; 137Cs) syngeneic
unseparated splenocytes) and incubated with UV-inactivated
EB at a ratio of 1:10. Concanavalin A (SigmaeAldrich; St.
Louis, MO) was used as a positive stimulant and tissue culture
media served as a negative control. At the end of 96 h of incu-
bation, 1.0 mCi of [methyl-3H] thymidine (47 Ci/mmol; Amer-
sham, Arlington Heights, IL) were added to each well and the
uptake of the [3H] thymidine was measured after 18 h using a
scintillation counter (Beckman Instruments, Fullerton, CA).
Levels of IFN-g and IL-6 in supernatants from splenic T cells
stimulated with UV-inactivated EB for 48 h were determined
using ELISA kits BD Pharmingen, San Diego, CA [22].2.6. Evaluation of disease burden and infection
following the i.n. challengeAfter the i.n. challenge, mice were weighed daily for 10
days [35,22]. At day 10 post-challenge (D10 p.c.) mice were
euthanized, their lungs weighed, homogenized and serial 10-
fold dilutions were used to infect Hela-229 cells. Following
centrifugation the plates were incubated for 30 h at 37 C in a
5% CO2 incubator. Inclusions were visualized with a cocktail
of Chlamydia-specific monoclonal antibodies and were
counted using a light microscope [33]. The lower limit of
detection was 50 IFU/mouse lungs.2.7. Determination of the local immune responses in the
lungs at D10 p.cTo assess the local immune responses in the lungs at the
time of euthanasia, the titers of C. muridarum-specific IgA and
levels of IFN-g were determined by ELISAs using a 1:2
dilution of the supernatants of homogenized lungs from each
mouse as previously described [34].2.8. Statistical analysesThe One-way ANOVA with the Dunnett's multiple com-
parisons test, KruskaleWallis test or the Repeated Measures
ANOVA, were employed to determine the significance of the
differences among groups.
3. Results3.1. Computational modeling of TC0583 suggests it is a
member of the putative C. muridarum V-type ATP
synthase complexAll members of Chlamydia encode an apparent V-type
ATPase through six functionally annotated genes (subunits K,
I, B, D, A and E encoded by genes CT304-CT308 and CT310,
respectively, using C. trachomatis serovar D annotation [17])
that are transcribed within a single operon [36e38,19]. Within
this set of co-transcribed genes is a single protein of unknown
function (CT309) that belongs to DUF2764. BLAST analysis
of the CT309 amino acid sequence fails to identify any sta-
tistically significant targets (E value < 1.0e10) outside of
Chlamydia. Homologs to CT309 are found throughout all
members of Chlamydia including within C. muridarum, where
TC0583 shares 89% sequence identity.
Genes found within a co-transcribed operon often encode
proteins that function within the same pathway, which in-
dicates that TC0583 could potentially interact with the V-type
ATPase. To gain support for this hypothesis, structural
modeling of TC0583 was performed. The highest confidence
computational model generated by I-TASSER (e.g. C-
score > 1.5 [39]) is comprised of an all a-helical fold
assembled into a tapered cylinder (Fig. 1) with a C-score of
0.89 [24e26]. The protein structure homology server DALI
[40] was then used to predict the top structural and functional
homologs to the TC0583 model. The highest scoring hit (Z-
score ¼ 31.2) was the V-type ATPase subunit C from Thermus
thermophilus (TtAtpC; PDB ID: 1R5Z [41]). Structural
alignment of TC0583 and TtAptC (Fig. 1) indicates a highly
similar topology (RMSD 1.71 Å over 248/266 Ca atoms),
despite sharing only 11.7% sequence identity across the entire
polypeptide. The C-subunit is a peripheral membrane
component of the V-type ATPase that is proposed to physically
link the V0 and V1 domains [41]. Further insights into the
potential molecular function of TC0583 are limited by the lack
of C-subunit structures (TtAtpC is currently the only one) and
the absence of TC0583 sequence-level homologs outside
Chlamydia.3.2. Characterization of the humoral and cellular
immune responses following vaccinationFollowing vaccination the humoral and the cellular immune
responses were characterized the day before the i.n. challenge.
Antibodies to C. muridarum were assessed by an ELISA using
EB as the antigen. As shown in Table 1, mice immunized with
TC0583 had very low serum IgG antibody titers to EB (159
Fig. 1. Computational modeling of TC0583 suggests it is V-type ATPase subunit C. Computational model of TC0583 from C. muridarum (generated by I-
TASSER [24e26]) is shown in cartoon ribbon format (colored blue). Crystal structure of T. thermophilus V-type ATPase subunit C (PDB ID: 1R5Z) is shown as
electron surface representation and colored gray. TC0583 aligns to the T. thermophilus V-type ATPase subunit C with an RMSD of 1.71 Å across 248/266 modeled
Ca residues, despite only 11.7% sequence identity between the two proteins.
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had no measurable C. muridarum specific IgG antibodies
(<100). Mice receiving a combination of both
TC0582 þ TC0583 had an IgG GMT of 340 (100e800).
Serum from mice vaccinated with rMOMP, or EB, had high
IgG antibody titers, 129,016 (102,400e204,800) and 72,408
(51,200e102,400), respectively. Anti-rMOMP IgG antibodies
were only detected in animals immunized with rMOMP
(258,032; 204,800e409,600) or EB (3200; 3200e3200). The
two negative control groups, immunized with PBS-C/M, or
MEM, had no C. muridarum specific IgG antibodies.
Following absorption of the sera with recombinant MBP,
from mice immunized with TC0583 or TC0582 þ TC0583,
antibodies were also measured using recombinant proteins as
antigens (Table 1). Animals vaccinated with TC0583 had IgG
antibody levels against this protein (3200; 1600e6400) that
were similar to those mice immunized with
TC0582 þ TC0583 (2263; 1600e3200). Mice immunized
with TC0582 had high levels of IgG to this antigen (162,550;
102,400e204,800) and animals immunized with
TC0582 þ TC0583 also had high IgG antibody levels (64,508;Table 1
Serum IgG antibody geometric mean titer (GMT) (range) the day before the i.n. c
Experimental groups Anti-C. muridarum EB Anti-rMOMP
TC0583 159a,b,c (100e200) <100 (<100e<100
TC0582 <100b,d,e (<100e<100) <100 (<100e<100
TC0582 þ TC0583 340a,b,c (100e800) <100 (<100e<100
rMOMP 129,016a,c,d,e (102,400e204,800) 258,032a,c,d,e (204,8
PBS-C/M <100 (<100e<100) <100 (<100e<100
EB 72,408 (51,200e102,400) 3200 (3200e3200)
MEM <100 (<100e<100) <100 (<100e<100
a P < 0.05 by One-way ANOVA when compared to PBS-C/M immunized group
b P < 0.05 by One-way ANOVA when compared to rMOMP immunized group.
c P < 0.05 by One-way ANOVA when compared to TC0582 immunized group.
d P < 0.05 by One-way ANOVA when compared to TC0583 immunized group.
e P < 0.05 by One-way ANOVA when compared to TC0582 þ TC0583 immun51,200e102,400) to TC0582. Positive control mice inoculated
i.n. with live EB had a low antibody titer to TC0582 (283;
100e400) and no detectable anti-TC0583 antibodies (<100).
Mice immunized with TC0583, TC0582 or
TC583 þ TC582, showed significantly higher T-cell prolifer-
ative responses to EB (3092 ± 3487; SI 5.1 ± 3.3),
(1213 ± 1042; SI 4.4 ± 2.9) and (2035 ± 1342; SI 6.3 ± 2.7),
respectively, compared to control animals vaccinated with
PBS C/M (229 ± 119; SI 2.2 ± 0.6) (P < 0.05; Table 2). Mice
vaccinated with rMOMP had strong proliferative responses
(2205 ± 122; SI 16.5 ± 3.7). The most robust lymphoproli-
ferative responses were observed in control mice inoculated
i.n. with live EB (5248 ± 1161; SI 39.4 ± 8.5).
Low levels of IFN-g (pg/ml), in supernatants from EB-
stimulated splenocytes, were found in mice vaccinated with
TC0583 (299 ± 73), TC0582 (226 ± 59), or the
TC582 þ TC583 combination (93 ± 7) (Table 2). None of
these results were statistically significantly different from each
other but TC0583 and TC0582 immunized groups were
significantly higher compared to negative controls group
immunized with PBS-C/M (49 ± 45). In mice vaccinated withhallenge.
Anti-TC0583 Anti-TC0582
) 3200a,b,c (1600e6400) <100 (<100e<100)
) <100 (<100e<100) 162,550a,b,d,e (102,400e204,800)
) 2263a,b,c (1600e3200) 64,508a,b,c,d (51,200e102,400)
00e409,600) <100 (<100e<100) <100 (<100e<100)
) <100 (<100e<100) <100 (<100e<100)
<100 (<100e<100) 283 (100e400)
) <100 (<100e<100) <100 (<100e<100)
.
ized group.
Table 2
In vitro splenic T-cells proliferative responses and IFN-g and IL-6 levels detected in the supernatants of proliferating splenic T-cells stimulated with UV-treated EB.
Experimental groups DCPM SI IFN-g (pg/ml) IL-6 (pg/ml)
TC0583 3092 ± 3487a,b 5.1 ± 3.3a 299 ± 73a,c 121 ± 18a,b
TC0582 1213 ± 1042a 4.4 ± 2.9 226 ± 59a,c 59 ± 6a,c
TC0582 þ TC0583 2035 ± 1342a 6.3 ± 2.7a 93 ± 7c 60 ± 5a,c
rMOMP 2205 ± 122a 16.5 ± 3.7a 4406 ± 766a 126 ± 8a
PBS-C/M 229 ± 119 2.2 ± 0.6 49 ± 45 22 ± 6
EB 5248 ± 1161 39.4 ± 8.5 29,274 ± 4283 221 ± 37
MEM 546 ± 591 1.9 ± 0.7 <15 ± 4 <10 ± 5
A ratio of 10:1, EB to splenocytes, was used.
DCPM: difference in counts per minute between EB stimulated and medium stimulated T-cells.
SI: Stimulation Index: Ratio of CPM in supernatants from EB stimulated T-cells over CPM from medium stimulated T-cells.
a P < 0.05 by One-way ANOVA when compared PBS-C/M immunized group.
b P < 0.05 by One-way ANOVA when compared to TC0582 þ TC0583 immunized group.
c P < 0.05 by One-way ANOVA when compared to rMOMP immunized group.
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significantly higher than in animals immunized with TC0582,
TC0583 or a combination of these two antigens (P < 0.05).
The highest level of IFN-g was detected in supernatants from
mice vaccinated with EB (29,274 ± 4283).
Low levels of IL-6 were measured in spleen supernatants
from all groups of mice (Table 2). However, the levels of IL-6
in mice immunized with TC0583, TC0582, or the combina-
tion, were significantly higher than in the negative control
group (P < 0.05).3.3. Changes in body weight of mice following the C.
muridarum i.n. challengeFig. 2. Systemic disease burden following the i.n. challenge with C. mur-
idarum. A. Daily percentage change in mean body weight following the i.n.
challenge (*, P < 0.05 and **, P > 0.05 by the Repeated Measures ANOVA).
B. Percentage change in mean body weight at D10 following the i.n. chal-
lenge. The mean is shown as a horizontal line. Each symbol represents a single
animal.As a measure of the systemic effects of the C. muridarum
i.n. challenge, the body weight was monitored. Except for
control animals immunized i.n. with live EB, all other groups
of mice rapidly lost weight from D2 to D4 p.c. (Fig. 2A). Mice
immunized with TC0583, TC0582, PBS C/M, or MEM-0, lost
between 10 and 12% of their initial body weight while animals
vaccinated with rMOMP, or the TC0582 þ TC0583 combi-
nation, lost between 4 and 6% by D4 p.c. Subsequently, mice
immunized with TC0583, or TC0582, lost another 4% and 2%,
respectively, of their initial weight, while mice vaccinated with
TC0582 þ TC0583, or rMOMP, maintained their weight. Over
the 10 day period mice immunized with TC0583, TC0582,
TC0582 þ TC0583, or rMOMP, had lost less body weight than
the controls immunized with PBS-C/M (P < 0.05). Animals
immunized with TC0582 þ TC0583 lost less body weight than
those immunized with TC0583 or TC0582 (P < 0.05). No
significant difference in body weight loss over the 10 day
period was observed in mice immunized with
TC0582 þ TC0583 when compared with the group vaccinated
with rMOMP (P > 0.05).
As shown in Fig. 2B and Table 3, at D10 p.c., the mean
body weight losses of mice vaccinated with TC0582
(11.97 ± 6.23%) or TC0582 þ TC0583 (5.91 ± 6.80%),
were significantly different from the group immunized with
PBS-C/M (18.68 ± 6.62%) (P < 0.05). The body weight
losses were not significantly different between TC0583(14.65 ± 7.75%) and TC0582, but were significantly higher
than the TC0582 þ TC0583, or rMOMP, vaccinated groups
(P < 0.05). The body weight loss of mice vaccinated with
TC0582 þ TC0583, or rMOMP (3.46 ± 4.32%), were not
statistically different (P > 0.05) from each other.3.4. Lungs weight at D10 p.cAs a measure of the local inflammatory responses, the
weight of the lungs (g) was determined at the time of
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Fig. 3. Local disease burden, titers of C. muridarum-specific IgA and levels of IFN-g present in the lungs at D10 p.c. A. Lung weight (g) at D10 after the i.n.
challenge. The mean is shown as a horizontal line. Each symbol represents a single animal. B. Number of Chlamydia IFU recovered from the lungs at D10 after the
i.n. challenge. The median is shown as a horizontal line. Each symbol represents a single animal. C. Levels of C. muridarum-specific IgA (OD405) detected in the
lungs at D10 following the i.n. challenge. The mean is shown as a horizontal line. Each symbol represents a single animal. D. Amounts of IFN-g (pg/ml) detected
in the lungs at D10 after the i.n. challenge. The mean is shown as a horizontal line. Each symbol represents a single animal. a: P < 0.05 by One-way ANOVAwhen
compared to PBS-C/M immunized group. b: P < 0.05 by One-way ANOVA when compared to rMOMP immunized group.
Table 3
Disease burden and yields of C. muridarum recovered from the lungs at day 10 p.c.
Experimental groups % Change in body weight [mean ±1SE] Lungs weight (g) [mean ±1SD] No. IFU X106 [median (range)]
TC0583 14.65 ± 7.75a,b 0.31 ± 0.03a 103 (5e1034)f,g
TC0582 11.97 ± 6.23a,b,c 0.32 ± 0.05a 66 (9e1261)f,g
TC0582 þ TC0583 5.91 ± 6.80c,d 0.29 ± 0.04a,e 44 (0.31e604)f,g
rMOMP 3.46 ± 4.32c 0.22 ± 0.04c 0.07 (0.02e159)f
PBS-C/M 18.68 ± 6.62 0.33 ± 0.04 747 (96e9740)
EB 2.81 ± 1.84 0.19 ± 0.02 BLD (BLD e BLD)h
MEM 21.94 ± 4.60 0.32 ± 0.03 906 (438e11,778)
a P < 0.05 by One-way ANOVA when compared to rMOMP immunized group.
b P < 0.05 by One-way ANOVA when compared to TC0582 þ TC0583 immunized group.
c P < 0.05 by One-way ANOVA when compared to PBS-C/M immunized group.
d P < 0.05 by One-way ANOVA when compared to TC0583 immunized group.
e P < 0.1 by One-way ANOVA when compared to PBS-C/M immunized group.
f P < 0.05 by KruskaleWallis test when compared to PBS-C/M immunized group.
g P < 0.05 by KruskaleWallis test when compared to rMOMP immunized group.
h BLD: below the limit of detection (50 IFU/mouse lungs).
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significant differences (P > 0.05) in the mean weight of the
lungs were observed between the groups of mice immunized
with TC0583 (0.31 ± 0.03), TC0582 (0.32 ± 0.05) and
TC0582 þ TC0583 (0.29 ± 0.04). The weight of the lungs in
these three groups was not significantly different from the
negative control mice immunized with PBS-C/M (0.33 ± 0.04)
(P > 0.05) although for the group vaccinated with
TC0582 þ TC0583 there was a trend (P > 0.1). However, they
were statistically significantly different from those of rMOMP
(0.22 ± 0.04) immunized mice (P < 0.05). The weight of the
lungs from mice vaccinated with rMOMP was not different
from that of the positive control group immunized with EB
(0.19 ± 0.02) (P > 0.05).3.5. Burden of C. muridarum infection in the lungsThe median (range) number of C. muridarum IFU recov-
ered from lungs of mice vaccinated with TC0583 was 103
(5e1034)  106 IFU, not statistically different from the
number of IFU recovered from lungs of mice immunized with
TC0582 [66 (9e1261)  106 IFU], or the TC0582 þ TC0583
combination [44 (0.31e604)  106 IFU]; (P > 0.05) (Fig. 3B
and Table 3). These were statistically different than the
number of IFU recovered from the negative control group
immunized with PBS-C/M [747 (96e9740)  106 IFU],
(P < 0.05). The most robust protection, among the animals
receiving a subunit vaccine, was observed in mice vaccinated
with the control rMOMP [0.07 (0.02e159)  106 IFU];
(P < 0.05 when compared with the other three groups
immunized with recombinant antigens). Animals immunized
with live EB, had negative cultures [below the limit of
detection (BLD): 50 IFU/mouse lungs].3.6. Local immune responses in lungs at D10 p.cTo determine immune local parameters that correlate with
protection we measured the levels of C. muridarum-specific
IgA and IFN-g in supernatants from lungs harvested at D10
p.c. (Fig. 3C and D). The mean OD405 values of Chlamydia-
specific IgA in the lungs of mice vaccinated with TC0583
(0.781 ± 0.145), TC0582 (0.742 ± 0.125), or
TC0582 þ TC0583 (0.727 ± 0.100), were not significantly
different among themselves, or the rMOMP control group
(0.835 ± 0.307), but were significantly higher than those of the
negative control immunized with PBS-C/M (0.432 ± 0.093)
(P < 0.05). As expected, mice inoculated with EB had the
highest C. muridarum-specific IgA levels (4.814 ± 0.692) in
the lungs.
The mean levels of IFN-g (pg/ml) present in the lung su-
pernatants at D10 p.c. in mice immunized with TC0583
(412 ± 127), TC0582 (401 ± 144), TC0582 þ TC0583
(380 ± 214), PBS-C/M (470 ± 71), or with MEM (456 ± 61)
were not statistically different among them (P > 0.05). The
amounts of IFN-g in mice vaccinated with rMOMP
(132 ± 186), or EB (13 ± 1), were statistically significantly
lower than the negative control groups (P < 0.05).4. Discussion
Our results demonstrated that vaccines formulated with
TC0582, TC0583, or a combination of both, and a combina-
tion of adjuvants that favor a Th1-biased response, elicited
significant protective humoral and cellular immune responses
as determined by changes in body weight, weight of the lungs
and number of C. muridarum IFU recovered from the lungs.
Chlamydia do not solely rely on the host cell for production
of energetic substrates and, for an obligate intracellular path-
ogen, encode a surprising array of metabolic pathways
[42,17,43]. Despite the apparent presence of a complete V-
type ATPase, it seems likely that this macromolecular complex
is responsible for generating the transmembrane electro-
chemical potential gradient in Chlamydia (e.g. ATP hydrolysis
rather than synthesis) as obvious homologs to the majority of
the electron transport chain are absent. Computational
modeling suggests that hypothetical protein TC0583 (or
CT309 in C. trachomatis) is likely V-type ATPase subunit C.
Previous vaccination studies, with different subunits of the C.
muridarum V-type ATPase, indicated protection could be
achieved with TC0582 (subunit A) with the caveat that there is
sequence identity with the equivalent mouse homologs [15].
However, Cheng et al. [15] have shown that sera from mice
vaccinated with TC0582, or with EB, react with TC0582 but
not with the mouse AtpA protein and therefore, involvement
of this antigen in pathogenesis by production of autoantibodies
is unlikely. Rotary proton/sodium-translocating ATPases are
conserved throughout all kingdoms of life [14,15,44,45,37,46].
These insights along with the absence of sequence similarity
between TC0583 and eukaryotic V-type ATPases indicated
this protein warranted further analysis as a potential vaccine
candidate.
Attempts to control the worldwide epidemic of C. tracho-
matis genital infections using antibiotics have so far failed.
Vaccines are likely to be a more effective approach at con-
trolling these infections [11,10,9,47]. In this study, we deter-
mined the ability of two subunit components of a predicted
Chlamydia V-type ATPase to protect BALB/c mice against an
i.n. challenge with C. muridarum. TC0582 and TC0583 are
putative subunits (A and C, respectively) of the V-type ATPase
inner membrane associated macromolecular assembly.
Following immunization the humoral and cell-mediated
immune responses were determined. Mice immunized with
TC0582, or TC0583, or a combination of TC0582 and
TC0583, developed very low or not detectable levels of anti-
bodies when using C. muridarum EB as the antigen. This was
anticipated since these proteins are expressed at very low
levels in EB and are not surface exposed [46]. This premise
was supported when recombinant proteins, rather than EB,
were used as antigens in the ELISA. In this case high antibody
titers were measured in the groups of mice vaccinated with
single and combination of both antigens. Antibody titers were
higher in animals immunized with TC0582 than TC0583.
When the combination of both antigens was used to immunize
the antibody titer was also higher against TC0582. These
findings support the previous observation that TC0582 is a
252 D.F. Tifrea et al. / Microbes and Infection 18 (2016) 245e253more dominant antigen than TC0583. As determined by a
lymphoproliferative assay, using EB to stimulate spleen T-
cells, the three groups of mice immunized with TC0582,
TC0583, or a combination of both, mounted significant cell
mediated immune responses. Furthermore, measurement of
the levels of IFN-g in supernatants from stimulated T-cells,
were higher in these three groups than in the negative control
animals. Interestingly, the TC0582 þ TC0583 combination
elicited better protection than the individual antigens although
the levels of IFN-g were not higher than for each individual
antigen. Other immunological components, such as TNF-a,
could account for this protection [48]. Finco et al. [49] used
120 recombinant proteins from C. trachomatis serovar D to
screen sera from Chlamydia infected patients. Of the 79 pro-
teins that were recognized by human antibodies, five (CT119,
CT372, CT443, CT681 and CT823), also induced CD4þ/IFN-
g in mice infected with C. trachomatis, indicative of cell-
mediated immune responses. As shown here, TC0582 and
TC0583, at least in mice, can also induce humoral and cell
mediated immune responses when formulated with adjuvants
that favor a Th1 response.
Four weeks after the last immunization mice were chal-
lenged i.n. with C. muridarum. As determined by changes in
body weight and number of IFU recovered from the lungs
TC0582 and TC0583 elicited partial protective immune re-
sponses. We have previously tested TC0580, TC0581 and
TC0582 by themselves, or in combination, for their ability to
protect mice against an i.n. challenge with C. muridarum and
found TC0581 and TC0582 to be protective [15]. Combina-
tions of these antigens were also protective but the level of
protection was not additive [15]. We therefore, were very
interested in determining if a vaccine formulated with TC0582
and TC0583 could have additive effects. Our results show that,
based on changes in body weight, the combination of TC0582
and TC0583 had additive effects. Although, based on both
weight of the lungs and the number of IFU recovered, there
was a trend in the mice immunized with the combination
antigens to have better protection, the differences were not
statistically significant when compared with the results ob-
tained in the groups vaccinated with a single antigen. Additive
effects have been reported for chlamydial antigens, including
some that were not protective on their own, while other have
resulted in neutral effects. For example, Finco et al. [49]
observed an additive effect by combining protective, or none
protective antigens. In contrast, Yu et al. [50], like us, reported
neutral effects when using various antigen combinations.
Based on these observations, to assess the efficacy a chla-
mydial multisubunit vaccine, will require testing several
combinations of candidate antigens.
A potential shortcoming of using components of the V-type
ATPases macromolecular structures is the possible sequence
homology with the equivalent eukaryotic complex. BLAST
analysis of TC0583 failed to identify significant homology with
any eukaryotic or prokaryotic protein outside ofChlamydia. On
the other hand, protein structure homology modeling suggests
that TC0583 has structural similarity with V-type ATPase sub-
unit C (AtpC). The lack of sequence homology of TC0583 toany known eukaryotic protein can be an advantage over the use
of TC0582 as an antigen in a vaccine. TC0582 has ~40% amino
acid sequence identity with the eukaryotic ATP synthase subunit
A. Therefore, vaccination with TC0582 could potentially
induce antibodies that cross-reacted with the eukaryotic syn-
thase subunit and elicit an adverse reaction. In the mousemodel,
so far tested, this does not appear to be the case but could be a
shortcoming when vaccinating humans with a wide variety of
genetic backgrounds [15].
In conclusion, vaccination of mice with TC0583 elicited
moderate immune responses that were partially protective
against an intranasal challenge with C. muridarum. TC0583 in
combination with TC0582 further enhanced the protection.
TC0583 is highly conserved among all the C. trachomatis
serovars, has no sequence homology to a host protein and
therefore, should be considered as a potential candidate of a
multisubunit vaccine.
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